drugset
drugset / Trial / NCT02345213

A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)

NCT02345213 ↗

Phase 4 Completed 160 enrolled Eisai Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to confirm the efficacy of Aricept in patients with dementia with Lewy bodies (DLB).

Timeline

Start
2015-03-01
Primary completion
2017-05-15
Completion
2018-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 10 mg Oral

Indications

Lewy body dementia